Protara Capex To Revenue from 2010 to 2024
| TARA Stock | USD 2.94 0.34 13.08% |
Capex To Revenue | First Reported 2010-12-31 | Previous Quarter 0.0156 | Current Value 0.0138 | Quarterly Volatility 0.000976 |
Check Protara Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protara Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 268.5 K, Interest Expense of 1.4 M or Selling General Administrative of 15.3 M, as well as many indicators such as Price To Sales Ratio of 8.65, Dividend Yield of 0.0 or PTB Ratio of 0.3. Protara financial statements analysis is a perfect complement when working with Protara Therapeutics Valuation or Volatility modules.
Protara | Capex To Revenue |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Protara Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Protara Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Protara Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Protara Therapeutics Stock:Check out the analysis of Protara Therapeutics Correlation against competitors. For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protara Therapeutics. If investors know Protara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protara Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.64) | Return On Assets (0.28) | Return On Equity (0.46) |
The market value of Protara Therapeutics is measured differently than its book value, which is the value of Protara that is recorded on the company's balance sheet. Investors also form their own opinion of Protara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protara Therapeutics' market value can be influenced by many factors that don't directly affect Protara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protara Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protara Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protara Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.